Company / Return on Equity (ROE)
Denali Therapeutics Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-50.6%
FY2025
5-year range
-50.6% / 6.2%
FY2021-FY2025
Trend
-47.1%
vs FY2024
Sector context
#135 of 190
Health Care
What the data says
Denali Therapeutics Inc. reports negative total equity of -50.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-50.6% in FY2025 with a 5-year CAGR of -43.9%.
Declined from -14.1% to -50.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -56.7pp
- 5-Year Change
- -43.9pp
- 10-Year Change
- -
Sector benchmark
In line with sector averageTop 71% of 190This company -50.6% Sector average -50.4%
▼
In line with sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 47.1% year-over-year.
- Currently 0.1pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -50.6% | -47.1% |
| FY2024 | -34.4% | -144.0% |
| FY2023 | -14.1% | -328.0% |
| FY2022 | 6.2% | +112.4% |
| FY2021 | -50.0% | -654.8% |
| FY2020 | -6.6% | +65.0% |
| FY2019 | -18.9% | - |
| FY2018 | - | - |
| FY2017 | -18.9% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026